PharmGKB summary: very important pharmacogene information for CFTR

Pharmacogenet Genomics. 2015 Mar;25(3):149-56. doi: 10.1097/FPC.0000000000000112.

Authors

Ellen M McDonagh¹, John P Clancy, Russ B Altman, Teri E Klein

Affiliation

¹ Departments of aGenetics, Stanford School of Medicine bBioengineering, Stanford University, Stanford, California cDivision of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center dDepartment of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA.

No abstract available

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Aminophenols / pharmacology*
Aminophenols / therapeutic use
Clinical Trials as Topic
Cystic Fibrosis / drug therapy*
Cystic Fibrosis / genetics
Cystic Fibrosis Transmembrane Conductance Regulator / genetics*
Cystic Fibrosis Transmembrane Conductance Regulator / metabolism
Drug Therapy, Combination
Humans
Molecular Targeted Therapy
Polymorphism, Single Nucleotide / drug effects
Quinolones / pharmacology*
Quinolones / therapeutic use

Substances

Aminophenols
CFTR protein, human
Quinolones
Cystic Fibrosis Transmembrane Conductance Regulator
ivacaftor

Grants and funding